ERBIOSYS

ERbiosys.com is a precision oncology bioinformatics startup that focuses on research and development of an affordable genetic breast cancer test to advise women on an optimal treatment. To identify patterns leading to precise treatment recommendations we use our proprietary AI technology. The company has a special focus on: - identification of cancer signaling pathways based on multi-omics molecular information, - evaluation of drug toxicity for a particular person, - analysis of mechanisms of drug resistance, - research of alternative cancer treatment options (based on evidence gathered from stage 4 survivors), - providing recommendations by referencing NCCN and ESMO guidelines, clinical trials, PubMed, and other academic research publications.